425: NLS Pharmaceutics and Kadimastem Amend Merger Terms, Clarifying Share Split and Closing Conditions

NLS Pharmaceutics Ltd. and Kadimastem Ltd. have signed a fourth amendment to their merger agreement, clarifying the post-closing share split, cash requirements, and board election conditions to facilitate the transaction's completion.

Summary

• NLS Pharmaceutics Ltd. and Kadimastem Ltd. entered into a Fourth Amendment to their Agreement and Plan of Merger on June 5, 2025.
• This amendment clarifies the definition and calculation of the Exchange Ratio for the merger.
• The initial target post-Closing fully diluted share split is set at 85% for Kadimastem shareholders and 15% for NLS Pharmaceutics shareholders.
• Potential adjustments to this share split will be based on Closing Cash, Closing Indebtedness, and Parent Adjusted Cash Amount.
• NLS Pharmaceutics is required to have at least USD $600,000 in gross funds at the Effective Time of the merger.
• The amendment specifies that NLS Pharmaceutics will abandon attempts to sell its Legacy Assets and dispose of them appropriately one year after closing, unless a binding agreement is reached or the board determines otherwise, or if related out-of-pocket expenditures exceed $100,000.
• A new closing condition requires NLS Pharmaceutics to convene a shareholder meeting to elect Kadimastem board members to the NLS board, effective at the Effective Time.
• The parties remain committed to completing the merger as soon as possible.

Sentiment

Score: 6

Explanation: The document indicates continued progress and commitment towards the merger, which is positive. However, the fact that this is the fourth amendment suggests complexities and potential delays, tempering overall positive sentiment. The clarification of terms is a step forward, but the ongoing adjustments imply challenges in reaching a definitive agreement.

Positives

• The Fourth Amendment clarifies key financial terms, such as the Exchange Ratio and share split, which can reduce ambiguity and facilitate the merger's completion.
• The parties explicitly state their continued focus and full commitment to completing the merger with utmost diligence, indicating strong intent.
• The establishment of a minimum cash requirement of USD $600,000 for NLS Pharmaceutics at closing provides a clear financial threshold for the combined entity.

Negatives

• This is the fourth amendment to the merger agreement since November 2024, suggesting ongoing complexities or disagreements in finalizing terms.
• The need for multiple amendments could indicate potential delays or challenges in reaching a definitive agreement and closing the transaction.
• The provision for abandoning the sale of Legacy Assets after one year, or if costs exceed $100,000, suggests potential difficulty in monetizing these assets, which could impact future value.

Risks

• Risks related to the companies' ability to complete the merger on the proposed terms and schedule.
• Uncertainties related to the satisfaction of the closing conditions outlined in the merger agreement.
• Risks and uncertainties related to the failure to timely, or at all, obtain shareholder approvals for the transaction.
• Potential for unexpected costs, charges, or expenses resulting from the transaction.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed merger.
• The potential for NLS Pharmaceutics to abandon attempts to sell Legacy Assets and dispose of them in a less optimal manner if a binding agreement is not reached within one year post-closing or if maintenance costs exceed $100,000.

Future Outlook

The companies are actively working to fulfill all commitments related to the merger process and adhere to regulatory requirements, with an expectation to complete the transaction as soon as possible. However, the completion is subject to various factors including satisfaction of closing conditions, timely shareholder approvals, and potential unexpected costs.

Management Comments

• "The Parties remain focused on and fully committed to aligning their efforts to completing the merger as soon as possible and with the utmost diligence."
• "The Parties are actively working to fulfill all commitments related to the process and adhere to the requirements set forth by all regulatory agents."

Industry Context

This amendment reflects ongoing consolidation and strategic realignments within the biotechnology and pharmaceutical sectors, where companies often seek to combine resources, pipelines, and market reach. The detailed adjustments to merger terms, particularly regarding share allocation and asset disposition, are common in complex cross-border transactions involving companies with distinct asset portfolios like NLS Pharmaceutics' Legacy Assets and Kadimastem's focus. The emphasis on regulatory adherence and shareholder approval highlights the stringent oversight in the life sciences industry.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders (Kadimastem): Expected to hold 85% of the combined company's fully diluted shares, subject to adjustments, indicating a significant ownership stake and control.
• Shareholders (NLS Pharmaceutics): Expected to hold 15% of the combined company's fully diluted shares, subject to adjustments, indicating a minority stake.
• Management/Employees: Significant changes expected in NLS Pharmaceutics' board and officer positions, with Kadimastem's leadership taking over, potentially impacting NLS employees.
• Creditors: The clarification of "Closing Indebtedness" and "Parent Adjusted Cash Amount" will impact the financial structure and liquidity of the combined entity, which is relevant for creditors.

Next Steps

• NLS Pharmaceutics to convene a shareholder meeting for the election of Kadimastem board members to the NLS board.
• The parties to continue working to fulfill all commitments and adhere to regulatory requirements for the merger.
• Investors and security holders are urged to read the proxy statement/prospectus and any other relevant documents filed with the SEC regarding the proposed transaction.
• NLS Pharmaceutics to dispose of Legacy Assets after one year from closing if no binding sale agreement is reached or if IP maintenance costs exceed $100,000.

Key Dates

Recommendation

Keywords

Merger Agreement, SEC Filing, NLS Pharmaceutics, Kadimastem, Exchange Ratio, Share Split, Closing Conditions, Corporate Governance, Biotechnology, Pharmaceuticals, Stem Cells, Acquisition, Form 425